These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 24864278)
41. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01. Fournel P; Vergnenégre A; Robinet G; Léna H; Gervais R; Le Caer H; Souquet PJ; Chavaillon JM; Bozonnat MC; Daurès JP; Chouaid C; Martel-Lafay I; Eur J Cancer; 2016 Jan; 52():181-7. PubMed ID: 26689864 [TBL] [Abstract][Full Text] [Related]
42. Treatment results of alternating chemoradiotherapy followed by proton beam therapy boost combined with intra-arterial infusion chemotherapy for stage III-IVB tongue cancer. Takayama K; Nakamura T; Takada A; Makita C; Suzuki M; Azami Y; Kato T; Hayashi Y; Ono T; Toyomasu Y; Hareyama M; Kikuchi Y; Daimon T; Mitsudo K; Tohnai I; Fuwa N J Cancer Res Clin Oncol; 2016 Mar; 142(3):659-67. PubMed ID: 26521257 [TBL] [Abstract][Full Text] [Related]
43. A Phase 2 Trial of Concurrent Chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: Results and Reflections Following Early Closure of a Single-Institution Study. Hoppe BS; Henderson R; Pham D; Cury JD; Bajwa A; Morris CG; D'Agostino H; Flampouri S; Huh S; Li Z; McCook B; Nichols RC Int J Radiat Oncol Biol Phys; 2016 May; 95(1):517-522. PubMed ID: 26774428 [TBL] [Abstract][Full Text] [Related]
44. Sequential chemoradiation therapy with vinorelbine, ifosfamide, and cisplatin in stage IIIB non-small cell lung cancer: a phase II study. Baldini E; Silvano G; Tibaldi C; Campoccia S; Cionini L; Conte P Semin Oncol; 2000 Feb; 27(1 Suppl 1):28-32. PubMed ID: 10697041 [TBL] [Abstract][Full Text] [Related]
45. Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study. Takase N; Hattori Y; Kiriu T; Itoh S; Kawa Y; Yamamoto M; Urata Y; Shimada T; Tsujino K; Soejima T; Negoro S; Satouchi M Respir Investig; 2016 Sep; 54(5):334-40. PubMed ID: 27566381 [TBL] [Abstract][Full Text] [Related]
46. Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer. Mornex F; Peignaux K; Germain T; Wautot V; Chouaki N; Bourayou N; Tourani JM Lung Cancer; 2013 Apr; 80(1):68-74. PubMed ID: 23332163 [TBL] [Abstract][Full Text] [Related]
47. Phase II study of vinorelbine plus carboplatin with concurrent radiotherapy in elderly patients with non-small cell lung cancer. Yamaguchi M; Hirata H; Ebi N; Araki J; Seto T; Maruyama R; Akamine S; Inoue Y; Semba H; Sasaki J; Okamoto T Jpn J Clin Oncol; 2020 Mar; 50(3):318-324. PubMed ID: 31804689 [TBL] [Abstract][Full Text] [Related]
48. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342 [TBL] [Abstract][Full Text] [Related]
49. Acute radiation esophagitis caused by high-dose involved field radiotherapy with concurrent cisplatin and vinorelbine for stage III non-small cell lung cancer. Kuroda Y; Sekine I; Sumi M; Sekii S; Takahashi K; Inaba K; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Murakami N; Morota M; Mayahara H; Ito Y; Tamura T; Nemoto K; Itami J Technol Cancer Res Treat; 2013 Aug; 12(4):333-9. PubMed ID: 23369154 [TBL] [Abstract][Full Text] [Related]
50. Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. Provencio M; Majem M; Guirado M; Massuti B; de Las Peñas R; Ortega AL; Dómine M; Marsé R; Sala MÁ; Paredes A; Morán T; Vázquez S; Coves J; Larriba JLG; Sánchez JM; Vicente D; Farré N; Fornos LF; Zapata I; Franco F; Serna-Blasco R; Romero A; Isla D Lung Cancer; 2021 Mar; 153():25-34. PubMed ID: 33453470 [TBL] [Abstract][Full Text] [Related]
51. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Nguyen QN; Ly NB; Komaki R; Levy LB; Gomez DR; Chang JY; Allen PK; Mehran RJ; Lu C; Gillin M; Liao Z; Cox JD Radiother Oncol; 2015 Jun; 115(3):367-72. PubMed ID: 26028228 [TBL] [Abstract][Full Text] [Related]
52. Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review. Lesueur P; Martel-Laffay I; Escande A; Kissel M; Locher C; Gervais R; Schott R; Vergnenegre A; Chouaid C Expert Rev Anticancer Ther; 2018 Nov; 18(11):1159-1165. PubMed ID: 30173589 [TBL] [Abstract][Full Text] [Related]
53. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer. Cardenal F; Arnaiz MD; Morán T; Jové J; Nadal E; Porta R; Solé JM; Brao I; Palmero R; Fuentes R; Núñez I; Caveda E; Cassinello A Lung Cancer; 2011 Oct; 74(1):69-74. PubMed ID: 21353323 [TBL] [Abstract][Full Text] [Related]
54. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group. Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975 [TBL] [Abstract][Full Text] [Related]
55. S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706). Ichinose Y; Seto T; Sasaki T; Yamanaka T; Okamoto I; Takeda K; Tanaka M; Katakami N; Sawa T; Kudoh S; Saka H; Nishimura Y; Nakagawa K; Fukuoka M J Thorac Oncol; 2011 Dec; 6(12):2069-75. PubMed ID: 22052226 [TBL] [Abstract][Full Text] [Related]
56. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer. Clark JI; Kancharla K; Qamar R; Fisher S; Hantel A; Panganiban J; Millbrandt L; Albain KS Lung Cancer; 2001 Nov; 34(2):271-7. PubMed ID: 11679186 [TBL] [Abstract][Full Text] [Related]
57. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC). Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556 [TBL] [Abstract][Full Text] [Related]
58. Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial. Hallqvist A; Bergström S; Björkestrand H; Svärd AM; Ekman S; Lundin E; Holmberg E; Johansson M; Friesland S; Nyman J Lung Cancer; 2018 Aug; 122():180-186. PubMed ID: 30032828 [TBL] [Abstract][Full Text] [Related]
59. Concurrent Chemo-Proton Therapy Using Adaptive Planning for Unresectable Stage 3 Non-Small Cell Lung Cancer: A Phase 2 Study. Iwata H; Akita K; Yamaba Y; Kunii E; Takakuwa O; Yoshihara M; Hattori Y; Nakajima K; Hayashi K; Toshito T; Ogino H; Shibamoto Y Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1359-1367. PubMed ID: 33227444 [TBL] [Abstract][Full Text] [Related]
60. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]